Search Results - "Zilocchi, C"

Predictive biomarkers of response to the tubulin-binding agent DM4 in colorectal cancer preclinical models by El-Murr, N, Nicolazzi, C, Calvet, L, Blot, L, Lefebvre, A.M, Theilhaber, J, Zilocchi, C, Demers, B, Blanc, V, Combeau, C, Sidhu, S.S, Chiron, M, Henry, C

“…Background: DM4, a maytarisine derivative, is a potent cytotoxic agent that binds to tubulin and inhibits the assembly of microtubules leading to efficient…”
Get full text

First-in-human phase I trial of the anti-CEACAM5 antibody–drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848) by Gazzah, A, Stjepanovic, N, Ryu, M.H, Tabernero, J, Soria, J.C, Bedard, P, Kang, Y.K, Bahleda, R, Guillemin-Paveau, H, Henry, C, Hatteville, L, Zilocchi, C, Demers, B, Hierro, C

“…An abstract of the study by Gazzah et al evaluating the first-in-human phase I trial of the anti-CEACAM5 antibody-drug conjugate SAR408701 in patients with…”
Get full text

Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine by Rodolfo, M, Zilocchi, C, Cappetti, B, Parmiani, G, Melani, C, Colombo, M P

“…The colon adenocarcinoma C26, carrying two endogenous tumor-associated antigens (TAA) recognized by CTL, has been transduced with the gene coding for the human…”
Get full text

352 - Predictive biomarkers of response to the tubulin-binding agent DM4 in colorectal cancer preclinical models by El-Murr, N., Nicolazzi, C., Calvet, L., Blot, L., Lefebvre, A.M., Theilhaber, J., Zilocchi, C., Demers, B., Blanc, V., Combeau, C., Sidhu, S.S., Chiron, M., Henry, C.

Get full text

23 - First-in-human phase I trial of the anti-CEACAM5 antibody–drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848) by Gazzah, A., Stjepanovic, N., Ryu, M.H., Tabernero, J., Soria, J.C., Bedard, P., Kang, Y.K., Bahleda, R., Guillemin-Paveau, H., Henry, C., Hatteville, L., Zilocchi, C., Demers, B., Hierro, C.

Get full text

528PAFLIBERCEPT + FOLFIRI FOR TREATMENT OF METASTATIC COLORECTAL CANCER AFTER OXALIPLATIN FAILURE: 4TH INTERIM SAFETY DATA FROM THE GLOBAL AFLIBERCEPT SAFETY AND QUALITY-OF-LIFE PROGRAM (ASQOP/AFEQT STUDIES) by Frassineti, L., Di Bartolomeo, M., Heinemann, V., Thomas, A.L., Taieb, J., Lledo, G., Moore, Y., Zilocchi, C., Brette, S., Sobrero, A., Bordonaro, R.

“…Abstract Aim: In VELOUR, aflibercept (ziv-aflibercept in the US) + FOLFIRI demonstrated a statistically significant improvement in overall survival vs placebo…”
Get full text

Aflibercept + Folfiri for Treatment of Metastatic Colorectal Cancer After Oxaliplatin Failure: 4Th Interim Safety Data from the Global Aflibercept Safety and Quality-Of-Life Program (Asqop/Afeqt Studies) by Frassineti, L., Di Bartolomeo, M., Heinemann, V., Thomas, A.L., Taieb, J., Lledo, G., Moore, Y., Zilocchi, C., Brette, S., Sobrero, A., Bordonaro, R.

Get full text

529PQUALITY OF LIFE (QOL) ON THE AFLIBERCEPT/FOLFIRI REGIMEN: 4TH INTERIM ANALYSIS OF THE GLOBAL AFLIBERCEPT SAFETY AND HEALTH-RELATED QOL PROGRAM by Taieb, J., Bordonaro, R., Bencardino, K., Ciuffreda, L., Di Costanzo, F., Di Bartolomeo, M., Thomas, A.L., Kröning, H., Alfonso, P. García, Borg, C., Moore, Y., Brette, S., Zilocchi, C., Joulain, F., Naoshy, S., Garreau-Laporte, P., Dochy, E., Lledo, G., Sobrero, A.

“…Abstract Aim: In the phase 3 VELOUR trial, aflibercept (ziv-aflibercept in the United States) + FOLFIRI significantly improved overall survival vs FOLFIRI…”
Get full text

Quality of Life (Qol) on the Aflibercept/Folfiri Regimen: 4Th Interim Analysis of the Global Aflibercept Safety and Health-Related Qol Program by Taieb, J., Bordonaro, R., Bencardino, K., Ciuffreda, L., Di Costanzo, F., Di Bartolomeo, M., Thomas, A.L., Kröning, H., Alfonso, P. García, Borg, C., Moore, Y., Brette, S., Zilocchi, C., Joulain, F., Naoshy, S., Garreau-Laporte, P., Dochy, E., Lledo, G., Sobrero, A.

Get full text

IL-4-Transduced Tumor Cell Vaccine Induces Immunoregulatory Type 2 CD8 T Lymphocytes That Cure Lung Metastases Upon Adoptive Transfer by Rodolfo, Monica, Zilocchi, Chiara, Accornero, Paola, Cappetti, Barbara, Arioli, Ivano, Colombo, Mario P

“…Vaccinations with tumor cells engineered to produce IL-4 prolonged survival and cured 30% of mice bearing pulmonary metastases, an effect abrogated by in vivo…”
Get full text

Phase I dose escalation study of SR271425 administered as 24-hour intravenous continuous infusion in patients with refractory solid tumors by de Braud, F., Sessa, C., Gallerani, E., Curigliano, G., Cipolla, C., Columbo, A., Gallino, A., Schackleton, G., Zilocchi, C., Chadjaa, M.

“…Abstract only…”
Get full text

Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor by Zilocchi, C, Stoppacciaro, A, Chiodoni, C, Parenza, M, Terrazzini, N, Colombo, M P

“…We analyzed the ability of interferon (IFN)-gamma knockout mice (GKO) to reject a colon carcinoma transduced with interleukin (IL)-12 genes (C26/IL-12)…”
Get full text

Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor- associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines by Rodolfo, M, Zilocchi, C, Melani, C, Cappetti, B, Arioli, I, Parmiani, G, Colombo, MP

“…We have compared the therapeutic activity and characterized the antitumor response induced by IL-12 and IL-2 gene-transduced tumor cell vaccines. Mice bearing…”
Get full text

A case of hypoglycemia sensitive to leucine by ZILOCCHI, C

Get more information

IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases by RODOLFO, M, MELANI, C, ZILOCCHI, C, CAPPETTI, B, LUISON, E, ARIOLI, I, PARENZA, M, CANEVARI, S, COLOMBO, M. P

“…We evaluated whether antibody response correlates with tumor therapy by cytokine gene-modified tumor cell vaccines. To characterize the antibody (Ab) response…”
Get full text

Interferon gamma -independent Rejection of Interleukin 12-transduced Carcinoma Cells Requires CD4 super(+) T Cells and Granulocyte/Macrophage Colony-stimulating Factor by Zilocchi, C, Stoppacciaro, A, Chiodoni, C, Parenza, M, Terrazzini, N, Colombo, M P

“…We analyzed the ability of interferon (IFN)- gamma knockout mice (GKO) to reject a colon carcinoma transduced with interleukin (IL)-12 genes (C26/IL-12)…”
Get full text

575 Dose finding study of oral vinorelbine (VRL) in combination with capecitabine (CAP) in patients with metastatic breast cancer (MBC) by Nole, F., Catania, C., Sanna, G., Munzone, E., Corsetto, L., Longerey, B., Saindon, A., Zilocchi, C., Laffranchi, B., Goldhirsch, A.

Get full text

The Silver-Russel syndrome by Sarotti, M, Zilocchi, C, Bianchi, P, Faraci, C, Marenzi, C, Martinelli, D, Escobar, R

“…The authors report a case of Silver-Russel syndrome with severe deficit growth observed since intrauterine life. They describe the major features, that are…”
Get more information

Fetofetal transfusion in monochorial twins by Zilocchi, C

Get more information

Considerations on therapy of 56 cases of leukemia in childhood by Zilocchi, C

Get more information